<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664544</url>
  </required_header>
  <id_info>
    <org_study_id>MCI-186-E05</org_study_id>
    <secondary_id>2018-001163-23</secondary_id>
    <nct_id>NCT03664544</nct_id>
  </id_info>
  <brief_title>PK Study in Subjects With Severe Hepatic Impairment</brief_title>
  <acronym>MCI-186-E05 HP</acronym>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose study in male and female subjects with severe hepatic
      impairment and in male and female subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events</measure>
    <time_frame>Day -1 to Day 7</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Half-life (t½)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Total Clearance (CL)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)</measure>
    <time_frame>Day 1 to 3</time_frame>
    <description>Unchanged MCI-186</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Severe Hepatic Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Subjects with severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HP PK MCI-186</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV PK MCI-186</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCI-186</intervention_name>
    <description>30 mg MCI-186 will be administered intravenously over 60 minutes.</description>
    <arm_group_label>Subjects with normal hepatic function</arm_group_label>
    <arm_group_label>Subjects with severe hepatic impairment</arm_group_label>
    <other_name>Edaravone</other_name>
    <other_name>Radicava</other_name>
    <other_name>Radicut</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects

          -  1. Able to provide written informed consent to participate in this study after reading
             the participant information sheet and Informed Consent Form (ICF), and after having
             the opportunity to discuss the study with the Investigator or designee.

          -  2. Male or female subjects age 18 to 75 years (inclusive) at signature of the ICF.

          -  3. In the Investigator's opinion, subject is able to understand the nature of the
             study and any risks involved in participation, and willing to cooperate and comply
             with the Protocol restrictions and requirements.

          -  4. A body weight of ≥50 kg and a body mass index (Quetelet index) ranging from 18 to
             37 kg/m2 (inclusive) at Screening and Day -1.

          -  5. Female subjects who are:

               1. postmenopausal for at least 1 year, confirmed by follicle-stimulating hormone
                  assessment (&gt;40 mIU/mL), or

               2. surgically sterilised (hysterectomy, bilateral oophorectomy or salpingectomy), or

               3. congenital sterility. Female subjects of child-bearing potential must practice
                  effective contraception (see Protocol body) from the Screening Visit or at least
                  2 weeks before IMP administration, until 30 days after IMP dosing. Male subject
                  must practice effective contraception from the time of IMP dosing until 90 days
                  after IMP dosing. Adhering to strict abstinence is considered an accepted
                  contraceptive method.

        Hepatic impaired subjects (in addition)

          -  6. Diagnosis of cirrhosis due to parenchymal liver disease, which is documented in the
             medical history and physical examination and confirmed by at least one of the
             following: hepatic ultrasound, computed axial tomography scan, magnetic resonance
             imaging and/or liver biopsy. A Child-Pugh classification score of 10 to 14 obtained
             during the Screening period (i.e., within 21 days of IMP administration).

          -  7. Chronic (&gt;6 months) and stable hepatic impairment defined as no clinically
             significant change in disease status at least 14 days before Screening.

          -  8. Acceptable clinical conditions in the opinion of the Investigator on the basis of a
             physical examination, medical history, 12-lead electrocardiogram (ECG), vital signs
             and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis)
             at Screening, Day -1 and pre-dose on Day 1. Subjects with stable mild chronic
             concurrent diseases, such as degenerative joint disease, controlled diabetes,
             hypertension or hyperlipidaemia, etc. may be included.

        Healthy subjects (in addition)

          -  9. Subjects with normal hepatic function confirmed with tests within the normal
             reference range or results with minor deviations which are not considered by the
             Investigator to be clinically significant.

          -  10. Good health and free from clinically significant illness or disease in the opinion
             of the Investigator on the basis of a physical examination, medical history, ECG,
             vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and
             urinalysis) at Screening, Day -1 and pre-dose on Day 1.

        Exclusion Criteria:

        All subjects

          -  1. Presence or history of severe allergy to food, or any medical product or relevant
             excipient that is of clinical significance.

          -  2. Subjects who have previously been administered MCI-186.

          -  3. As a result of the medical screening process, the Investigator considers the
             subject not suitable for the study.

          -  4. Clinically significant 12-lead ECG abnormalities, including but not limited to,
             corrected QT interval using Fridericia's formula (QTcF) of &gt;450 ms (male subjects) or
             &gt;470 ms (female subjects) at Screening, Day -1 or before dosing.

          -  5. Any other history or condition (surgical or medical) of disease which will increase
             the risk to the subject, will affect the PK of the study drug, or will otherwise
             influence the assessments to be made in this study, in the opinion of the
             Investigator. Subjects who have undergone cholecystectomy may be included.

          -  6. History of drug abuse or tested positive for alcohol or drugs of abuse at Screening
             and Day -1, excluding drugs which may cause a positive drug or abuse test if medically
             indicated or prescribed.

          -  7. Subjects who regularly, or on average, drink more than 35 units of alcohol per week
             (one unit is equivalent to 300 mL of beer, 25 mL of spirits or 150 mL of wine).

          -  8. Presence of active infection requiring antibiotics.

          -  9. Positive test for human immunodeficiency virus antigen/antibody at Screening.

          -  10. Donation of one or more units of blood (450 mL) within 3 months prior to
             Screening, or plasma in the 7 days prior to Screening, or platelets in the 6 weeks
             prior to Screening, or the intention to donate blood within 3 months after the last
             Follow-up assessment.

          -  11. Participation in another study within the last month (if single dose), or at least
             4 months (if multiple dose), or within 10 times the half-life of the respective drug
             (whichever is longer) before Screening. For biologics, the minimum period is at least
             6 months before Screening, the period of the pharmacodynamic effect, or 10 times the
             half life of the respective drug, whichever is longer.

          -  12. Subject is currently taking non-permitted concomitant medication. The subjects
             with normal hepatic function are restricted from use of any concomitant medications
             (including paracetamol) unless discussed and agreed with the Sponsor. In subjects with
             hepatic impairment, the use of prescribed medications is permitted for hepatic or
             concomitant disease as described in the Protocol body.

          -  13. Not willing to abstain from consumption of coffee, tea, cola, energy drinks or
             chocolates from admission to the unit (Day -1) to discharge from the unit (Day 3).

          -  14. Uncontrolled, or untreated hypertension defined as a mean of three repeated
             measurements of systolic blood pressure &gt;180 mmHg and/or diastolic blood pressure &gt;100
             mmHg.

          -  15. Subjects have estimated glomerular filtration rate &lt;60 mL/min/1.73 m2 as
             determined by Modification of Diet in Renal Disease formula.

          -  16. Any condition associated with dehydration.

          -  17. Female subjects:

               1. who have a positive pregnancy test at Screening or on Day -1.

               2. who are pregnant, lactating or planning to become pregnant during the study.

        Hepatic impaired subjects (in addition)

          -  18. Subjects with severe ascites or pleural effusion which will, in the opinion of the
             Investigator, adversely affect the subject's ability to participate in the study.

          -  19. Subjects with severe encephalopathy (Grade III or IV).

          -  20. Subjects with sclerosing cholangitis.

          -  21. Serum albumin &lt;2.0 g/dL.

          -  22. Haemoglobin &lt;10 g/dL.

          -  23. Start of any new medication or any changes to a current dosage within 14 days
             before IMP administration.

        Healthy subjects (in addition)

          -  24. History or presence of any parenchymal hepatic disease.

          -  25. Positive test for hepatitis B surface antigen or hepatitis C virus antibody.

          -  26. History of or active suicidal ideation, or suicide attempt as evidenced by
             positive response to either Question 4 (active suicidal ideation with some intent to
             act) or Question 5 (active suicidal ideation with specific plan and intent) on the
             Columbia-Suicide Severity Rating Scale (C-SSRS; Screening Version).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Europe Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Centre</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Centre</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Centre</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <results_first_submitted>March 24, 2020</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Hepatic Impairment</keyword>
  <keyword>Healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03664544/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03664544/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HP PK MCI-186</title>
          <description>Subjects with severe hepatic impairment</description>
        </group>
        <group group_id="P2">
          <title>NHV PK MCI-186</title>
          <description>Subjects with normal hepatic function</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>HP PK MCI-186</title>
          <description>Subjects with severe hepatic impairment</description>
        </group>
        <group group_id="B2">
          <title>NHV PK MCI-186</title>
          <description>Subjects with normal hepatic function</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="7.9"/>
                    <measurement group_id="B2" value="53.0" spread="8.0"/>
                    <measurement group_id="B3" value="57.6" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.6" spread="146.8"/>
                    <measurement group_id="O2" value="280.3" spread="101.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473.90" spread="163.28"/>
                    <measurement group_id="O2" value="394.65" spread="160.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496.98" spread="183.81"/>
                    <measurement group_id="O2" value="416.34" spread="164.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (AEs) and Serious Adverse Events</title>
        <description>Number of adverse events</description>
        <time_frame>Day -1 to Day 7</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs) and Serious Adverse Events</title>
          <description>Number of adverse events</description>
          <population>Safety Analysis Set</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Drug reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Half-life (t½)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Half-life (t½)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="1.12"/>
                    <measurement group_id="O2" value="9.51" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Time to Reach Peak Concentration (Tmax)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.25" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.02" lower_limit="1.00" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Terminal Elimination Rate Constant (λZ)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.06"/>
                    <measurement group_id="O2" value="0.15" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Total Clearance (CL)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Total Clearance (CL)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.82" spread="21.49"/>
                    <measurement group_id="O2" value="78.72" spread="20.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Volume of Distribution at Steady State (Vss)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.86" spread="71.05"/>
                    <measurement group_id="O2" value="449.79" spread="438.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Volume of Distribution During the Terminal Phase (VZ)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.85" spread="130.06"/>
                    <measurement group_id="O2" value="1064.88" spread="888.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Mean Residence Time (MRT)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="1.87"/>
                    <measurement group_id="O2" value="5.51" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Unbound Area Under the Concentration-time Curve From Time Zero to Infinity (AUCu0-∞)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.41" spread="28.71"/>
                    <measurement group_id="O2" value="45.33" spread="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)</title>
        <description>Unchanged MCI-186</description>
        <time_frame>Day 1 to 3</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>HP PK MCI-186</title>
            <description>Subjects with severe hepatic impairment</description>
          </group>
          <group group_id="O2">
            <title>NHV PK MCI-186</title>
            <description>Subjects with normal hepatic function</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters of MCI-186: Unbound Total Clearance (Clu)</title>
          <description>Unchanged MCI-186</description>
          <population>PK population</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529.83" spread="200.93"/>
                    <measurement group_id="O2" value="702.10" spread="159.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day -1 to Day 7</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HP PK MCI-186</title>
          <description>Subjects with severe hepatic impairment</description>
        </group>
        <group group_id="E2">
          <title>NHV PK MCI-186</title>
          <description>Subjects with normal hepatic function</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDra v. 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>General Information</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Europe Ltd</organization>
      <phone>Please e-mail</phone>
      <email>regulatory@mt-pharma-eu.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

